Changing prescribing practice in CAPD patients in Korea: Increased utilization of low GDP solutions improves patient outcome

Nephrology Dialysis Transplantation

Volumn 21, Issue 10, 2006, Pages 2893-2899

  Lee, Ho Yung ^a   Choi, Hoon Young ^a   Park, Hyeong Cheon ^a   Seo, Bo Jeung ^b   Do, Jun Young ^c   Yun, Sung Ro ^d   Song, Hyun Yong ^d   Kim, Yeong Hoon ^e   Kim, Yong Lim ^f   Kim, Dae Joong ^g   Kim, Yong Soo ^h   Kim, Moon Jae ⁱ   Shin, Sug Kyun ^j  

^a Yonsei University College of Medicine   (South Korea)

^b Wallace Memorial Baptist Hospital   (South Korea)

^c Yeungnam University   (South Korea)

^d Konyang University   (South Korea)

^e Inje University   (South Korea)

^f Kyungpook National University   (South Korea)

^g Sungkyunkwan University   (South Korea)

^h The Catholic University of Korea   (South Korea)

ⁱ Inha University   (South Korea)

^j National Health Insurance Corporation   (South Korea)

more..

Author keywords

CAPD; Glucose degradation products; Patient survival; PH neutral; Prescribing practices

Indexed keywords

GLUCOSE DEGRADATION PRODUCT;

ADULT; AGE; AGED; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DIABETES MELLITUS; DIABETIC PATIENT; DIALYSATE; DISEASE FREE INTERVAL; FEMALE; HUMAN; KIDNEY FAILURE; KOREA; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MORTALITY; OBSERVATIONAL STUDY; PERITONITIS; PERSONAL EXPERIENCE; PH MEASUREMENT; PRESCRIPTION; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; DIALYSIS SOLUTIONS; FEMALE; GLUCOSE; HUMANS; KAPLAN-MEIER ESTIMATE; KAPLAN-MEIERS ESTIMATE; KOREA; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33749611755     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl393     Document Type: Article

References (20)

1. Alscher DM, Pauli-Magnus C, Kirchgessner J et al. A new lactate-based, plasticizerfree, neutral peritoneal dialysis fluid provided in a two-compartment system: Effect on peripheral leukocyte function. Kidney Int 2000; 86: 62-69
2. Wieslander AP, Kjellstrand PTT, Rippe B. Heat-sterilization of glucose-containing fluids for peritoneal dialysis: Biological consequences of chemical alterations. Perit Dial Int 1995; 15: 60-62
3. Wieslander A, Linden T. Glucose degradation and cytotoxicity in PD fluids. Perit Dial Int 1996; 16: 114-118
4. Witowski J, Bender TO, Gahl GM et al. Glucose degradation products and peritoneal membrane function. Perit Dial Int 2001; 21: 201-205
5. Plum J, Lordnejad MR, Grabensee B. The effect of alternative peritoneal dialysis solutions on cell viability, apoptosis/necrosis and cytokine expression in human monocytes. Kidney Int 1998; 54: 224-235
6. Mortier S, De Vriese AS, McLoughlin RM et al. Effects of conventional and new peritoneal dialysis fluids on leukocyte recruitment in the rat peritoneal membrane. J Am Soc Nephrol 2003; 14: 1296-1306
7. Rippe B, Simonsen O, Heimburger O et al. Long term clinical effects of a peritoneal dialysis fluid with less glucose degradation products. Kidney Int 2001; 59: 348-357
8. Williams JD, Topley N, Craig KJ et al. The Euro-Balance Trial: The effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 2004; 6: 408-418
9. Lee HY, Park HC, Seo BJ et al. Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (Balance). Perit Dial Int 2005; 25: 248-255
10. Kim SY, Jin DC, Bang BK. Current status of dialytic therapy in Korea. Nephrology 2003; 8: 2-9
11. Szeto CC, Lai KN, Wong TYH et al. Independent effects of residual renal function and dialysis adequacy on nutritional status and patient outcomes in continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1999; 34: 1056-1064
12. Chung SH, Heimburger O, Stenvinkel P et al. Association between residual renal function, inflammation and patient survival in new peritoneal dialysis patients. Nephrol Dial Transplant 2003; 18: 590-597
13. Bargmann JM, Thorpe KE, Churchill DN. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: A reanalysis of the CANUSA study. J Am Soc Nephrol 2001; 11: 2158-2162
14. Haag-Weber M, Haug U, Wieslander A, Nabut J, Deppisch R, Diurest Study Group. Decline of residual renal function (RRF) in peritoneal dialysis (PD) patients depends on uptake of carbonyl compounds (CC) from the peritoneal cavity: First data of a prespective clinical trial. J Am Soc Nephrol 2003; 14: 476A (Abstract)
15. Brown FI, Johnson DW. A randomized controlled trial to determine whether treatment with a neutral pH, low glucose degradation product dialysate (Balance) prolongs residual renal function in peritoneal dialysis patients. Perit Dial Int 2006; 26: 112-113
16. Tauer A, Zhang X, Schaub TP et al. Formation of advanced glycation end products during CAPD. Am J Kidney Dis 2003; 41: 57-60
17. Zeier M, Schwenger V, Deppisch R et al. Glucose degradation products in PD fluids: Do they disappear from the peritoneal cavity and enter the systemic circulation? Kidney Int 2003; 63: 298-305
18. Glorieux G, Helling R, Henle T et al. In vitro evidence for immune activating effect of specific AGE structures retained in uremia. Kidney Int 2004; 66: 1873-1880
19. Hartog JWL, Smit AJ, van Son WJ et al. Advanced glycation end products in kidney transplant patients: A putative role in the development of chronic renal transplant dysfunction. Am J Kidney Dis 2004; 43: 966-975
20. Teillet L, Verbeke P, Gouraud S et al. Food restriction prevents advanced glycation end product accumulation and retards kidney aging in lean rats. J Am Soc Nephrol 2000; 11: 1488-1497